Suppr
超能文献

能够在HLA - A24 +前列腺癌患者中诱导细胞和体液免疫反应的前列腺特异性抗原衍生表位。

Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.

作者信息

Harada Mamoru, Kobayashi Kazuhiko, Matsueda Satoko, Nakagawa Masami, Noguchi Masanori, Itoh Kyogo

机构信息

Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

出版信息

Prostate. 2003 Oct 1;57(2):152-9. doi: 10.1002/pros.10280.

DOI:10.1002/pros.10280

PMID:12949939

Abstract

BACKGROUND

We tried to identify prostate-specific antigen (PSA)-derived epitopes immunogenic in HLA-A24+ prostate cancer patients.

METHODS

Peripheral blood mononuclear cells (PBMCs) were in vitro stimulated with each of four different PSA peptides carrying the HLA-A24 binding motif, and their HLA-A24-restricted anti-tumor responses were examined using a parental HLA-A24-negative prostate cancer cell line (PC93) and its HLA-A24-expressing transfectant line (PC93-A24). Serum levels of immunoglobulin G (IgG) against PSA peptides were measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS

PBMCs, which were in vitro stimulated with either the PSA(152-160) or PSA(248-257) peptide, showed higher levels of IFN-gamma production and cytotoxicity against the PC93-A24 than against the PC93. IgG against the PSA(248-257) peptide was detected in half of the prostate cancer patients tested.

CONCLUSIONS

The PSA(152-160) and PSA(248-257) peptides could be appropriate target molecules in use for specific immunotherapy of HLA-A24+ prostate cancer patients.

摘要

背景

我们试图鉴定在HLA - A24阳性前列腺癌患者中具有免疫原性的前列腺特异性抗原（PSA）衍生表位。

方法

用四种携带HLA - A24结合基序的不同PSA肽分别体外刺激外周血单个核细胞（PBMC），并使用亲本HLA - A24阴性前列腺癌细胞系（PC93）及其表达HLA - A24的转染细胞系（PC93 - A24）检测其HLA - A24限制性抗肿瘤反应。通过酶联免疫吸附测定（ELISA）测量针对PSA肽的免疫球蛋白G（IgG）血清水平。